Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 down-regulation in hepatocellular carcinoma

Sorafenib (Nexavar), a multiple kinase inhibitor, is the only clinically approved drug for patients with advanced HCC. However, its therapeutic success is limited by the emergence of drug resistance. Here we found that p21 and pGSK3β(Ser9) are major players in the resistance to sorafenib. We recentl...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Giovannini, Catia, Baglioni, Michele, Toaldo, Marco Baron, Ventrucci, Cristiano, D'Adamo, Stefania, Cipone, Mario, Chieco, Pasquale, Gramantieri, Laura, Bolondi, Luigi
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2013
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3858550/
https://ncbi.nlm.nih.gov/pubmed/24113128
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים